Psychedelic and ketamine research trials in Israel
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
19 registered studies are counted in Israel. By compound: 4 psilocybin, 5 MDMA and 10 ketamine. By registry status: 8 recruiting, 1 not yet recruiting, 3 completed, 1 terminated and 6 status not reported. By phase: 1 early phase 1, 2 phase 1, 6 phase 2, 3 phase 3, 1 phase 4, 2 not applicable and 4 not reported. Reported start years run from 2007 (earliest) to 2026 (latest). Studies are linked to 12 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
9 of the 19 counted studies are listed in the registry as recruiting (8) or not yet recruiting (1), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Mitochondrial Function After Ketamine | NCT07399756 | Not yet recruiting | Not reported | 2026-02-01 | Sheba Medical Center, Ramat Gan |
| Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events | NCT07469098 | Recruiting | Phase 2 | 2025-12-24 | Sheba Medical Center, Beersheba |
| Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression | NCT07183748 | Recruiting | Phase 2 | 2025-12-01 | Beersheva Mental Health Center, Beersheba |
| Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers | NCT07079930 | Recruiting | Phase 1 | 2025-11-01 | Hadassah Medical Organization, Jerusalem |
| Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD | NCT07737054 | Recruiting | Early Phase 1 | 2025-07-22 | Tel-Aviv Sourasky Medical Center, Tel Aviv |
| Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | NCT05603104 | Recruiting | Phase 3 | 2025-04-27 | UMC Utrecht, Ramat Gan |
| Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD | NCT04882839 | Recruiting | Phase 2 | 2024-11-25 | Beersheva Mental Health Center, Beersheba |
| Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury | NCT06394284 | Recruiting | Phase 3 | 2024-02-18 | Herzog Hospital, Jerusalem |
| Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury. | NCT05732155 | Recruiting | Phase 2 | 2023-06-01 | HaEmek Medical Center, Israel, Afula |
At a glance
- 19 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 4 |
| MDMA | 5 |
| Ketamine | 10 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 8 | 42% |
| Not yet recruiting | 1 | 5% |
| Completed | 3 | 16% |
| Terminated | 1 | 5% |
| Status not reported | 6 | 32% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 5% |
| Phase 1 | 2 | 11% |
| Phase 2 | 6 | 32% |
| Phase 3 | 3 | 16% |
| Phase 4 | 1 | 5% |
| Not applicable | 2 | 11% |
| Not reported | 4 | 21% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 8 |
| 2020 to 2023 | 2 |
| 2015 to 2019 | 5 |
| 2010 to 2014 | 3 |
| Before 2010 | 1 |
All counted studies
All 19 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Mitochondrial Function After Ketamine | NCT07399756 | Not yet recruiting | Not reported | 2026-02-01 | Sheba Medical Center, Ramat Gan |
| Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events | NCT07469098 | Recruiting | Phase 2 | 2025-12-24 | Sheba Medical Center, Beersheba |
| Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression | NCT07183748 | Recruiting | Phase 2 | 2025-12-01 | Beersheva Mental Health Center, Beersheba |
| Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers | NCT07079930 | Recruiting | Phase 1 | 2025-11-01 | Hadassah Medical Organization, Jerusalem |
| Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD | NCT07737054 | Recruiting | Early Phase 1 | 2025-07-22 | Tel-Aviv Sourasky Medical Center, Tel Aviv |
| Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | NCT05603104 | Recruiting | Phase 3 | 2025-04-27 | UMC Utrecht, Ramat Gan |
| Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD | NCT04882839 | Recruiting | Phase 2 | 2024-11-25 | Beersheva Mental Health Center, Beersheba |
| Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury | NCT06394284 | Recruiting | Phase 3 | 2024-02-18 | Herzog Hospital, Jerusalem |
| Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury. | NCT05732155 | Recruiting | Phase 2 | 2023-06-01 | HaEmek Medical Center, Israel, Afula |
| 2-Year Study of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depression: Clinical Outcomes and Policy Recommendation | NCT07097025 | Completed | Not reported | 2020-01-01 | Maaynei Hayesha Medical Center, Bnei Brak |
| Ketamine Long Therm Follow Up Study | NCT04238039 | Status not reported | Not reported | 2019-12-14 | The Chaim Sheba Medical Center, Ramat Gan |
| Ketamine IV Classic Protocol : Five Years Follow up | NCT04824157 | Completed | Not reported | 2019-08-08 | Sheba Medical Center, Tel Litwinsky |
| The Effect of Intravenous Ketamine on Non Suicidal Self Injuries. | NCT04242914 | Status not reported | Phase 1 | 2019-02-25 | Tel-Aviv Sourasky Medical Center, Tel Aviv |
| Ketamine for Treatment Resistant MDD | NCT04021433 | Status not reported | Not applicable | 2018-09-01 | Hadassah Medical Organization, Jerusalem |
| D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression | NCT02772211 | Status not reported | Phase 4 | 2016-06-01 | Sheba Medical Center, Ramat Gan |
| Ketamine Infusions for Major Depression Disorder | NCT02219867 | Status not reported | Not applicable | 2014-08-01 | Sheba Medical Center, Ramat Gan |
| The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression | NCT02037503 | Status not reported | Phase 3 | 2014-01-01 | Tel-Aviv Sourasky Medical Center, Tel Aviv |
| Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD | NCT01689740 | Completed | Phase 2 | 2013-01-17 | Lykos Therapeutics, Be’er Ya‘aqov |
| Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel | NCT00402298 | Terminated | Phase 2 | 2007-05-27 | Lykos Therapeutics, Be’er Ya‘aqov |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | Ketamine
Institution hubs in this country
Institutions in this country with at least 3 counted studies. The number is that institution's own count of studies, which can include studies not shown above if the registry lists them under another country.
- Sheba Medical Center: 3 studies
- Tel-Aviv Sourasky Medical Center: 3 studies
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 9 |
| Post-traumatic stress disorder | 6 |
| Treatment-resistant depression | 5 |
| Bipolar disorder | 2 |
| Obsessive-compulsive disorder | 1 |
| Suicidal ideation and suicide risk | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | France | Brazil | China | Netherlands | Australia | Austria | Germany | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland